Objective To compare the effects of misoprostol versus ergometrine‐oxytocin for postpartum
haemorrhage (PPH) prevention, and provide important evidence to choose optimal agents …

Postpartum hemorrhage (PPH) is the commonest cause of maternal death worldwide.
Studies suggest that the use of misoprostol may be beneficial in clinical settings where …

Follow-up of the side effects of uterotonics used for postpartum hemorrhage is one of the
most important roles of health care providers. In this review, it is aimed to compare the side …

Materials and methods Systematic review of French and English literature by searching in
PubMed, The Cochrane Library and recommendations of international scholarly societies …

In order to systematically evaluate the clinical efficacy and safety of misoprostol versus
oxytocin in the prevention of postpartum hemorrhage, this paper provides evidence‐based …

Objective Postpartum hemorrhage (PPH) is a preventable condition and the main cause of
maternal death worldwide. Evidence on the effectiveness of misoprostol in the prevention of …

Background There is some evidence that suggests misoprostol may supplement the action
of oxytocin in preventing post-partum haemorrhage (PPH). The primary objective of this …

Background Oxytocin, the gold-standard treatment for post-partum haemorrhage, needs
refrigeration, intravenous infusion, and skilled providers for optimum use. Misoprostol, a …

Objective: To assess misoprostol's ability to prevent postpartum hemorrhage (PPH) where
no alternatives exist. Comparison to oxytocics demonstrates how similarly misoprostol …

Misoprostol is an effective and safe uterotonic for the prevention and treatment of postpartum
hemorrhage (PPH). A 600‐μg oral dose of misoprostol has been shown to prevent PPH in …